A Small Biotech With Two Complex Bispecific Antibody Candidates Benefits From A Blend Of Expertise And Flexibility

By Craig Parker, MBA, President & CEO, Surrozen

Surrozen’s President & CEO, Craig Parker, discusses how the expertise, resources and flexibility of Lonza have been fundamental in advancing its novel and complex bispecific antibody candidates that target the WNT pathway.

Targeted Regeneration

The ability of tissues to regenerate and maintain the structures of certain organs and systems is attributed to a fundamental biological pathway referred to as the Wingless-INT (WNT) signaling pathway. Although the WNT pathway has been studied for decades, no one has ever been able to intervene in this pathway and take advantage of its regenerative potential. Surrozen is a California-based small biotech working to change that paradigm.

Surrozen’s founding scientists contributed to a deeper understanding of the underlying biology of the WNT pathway and its role across diverse [normal and diseased] tissues. They identified the gene and explored the concept of targeting the pathway with non-naturally occurring molecules to initiate natural responses. Driven by this, Surrozen is developing bispecific antibodies that potently activate the WNT pathway, but in a very targeted manner and only in diseased tissue. We are excited to be advancing these first-in-class, novel molecules into the clinic for the first time in 2022.